Wladyslaw M.W. Gedroyc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wladyslaw M.W. Gedroyc has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Michael de Jode
Department of Interventional MRI, St. Mary's Hospital, Imperial College of Science, Technology and Medicine, London, UK
2 shared publicationsRita Joarder
Department of Interventional MRI, St. Mary's Hospital, Imperial College of Science, Technology and Medicine, London, UK
2 shared publications- Alessandro Napoli
Department of Radiological Sciences, Sapienza University of Rome, V.le Regina Elena, 324, 00180 Rome, Italy
1 shared publication - Andreas Melzer
IMSaT Institute for Medical Science and Technology, Dundee, UK
1 shared publication - Arik Hananel
Focused Ultrasound Foundation, Charlottesville, VA 22903, USA
1 shared publication - Chrit Moonen
University Medical Center Utrecht
1 shared publication
Latest Publications
- Open Access
- 1 August 2013
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 1 (1) , 13
The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus
Clinical use of high-intensity focused ultrasound (HIFU) under ultrasound or MR guidance as a non-invasive method for treating tumors is rapidly increasing. Tens of thousands of patients have been treated for uterine fibroid, benign prostate hyperplasia, bone metastases, or prostate cancer. Despite the methods' clinical potential, the liver is a particularly challenging organ for HIFU treatment due to the combined effect of respiratory-induced liver motion, partial blocking by the rib cage, and high perfusion/flow. Several technical and clinical solutions have been developed by various groups during the past 15 years to compensate for these problems. A review of current unmet clinical needs is given here, as well as a consensus from a panel of experts about technical and clinical requirements for upcoming pilot and pivotal studies in order to accelerate the development and adoption of focused ultrasound for the treatment of primary and secondary liver cancer.
- 1 August 2013
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 1 (1) , 13
Open AccessThe road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus
Clinical use of high-intensity focused ultrasound (HIFU) under ultrasound or MR guidance as a non-invasive method for treating tumors is rapidly increasing. Tens of thousands of patients have been treated for uterine fibroid, benign prostate hyperplasia, bone metastases, or prostate cancer. Despite the methods' clinical potential, the liver is a particularly challenging organ for HIFU treatment due to the combined effect of respiratory-induced liver motion, partial blocking by the rib cage, and high perfusion/flow. Several technical and clinical solutions have been developed by various groups during the past 15 years to compensate for these problems. A review of current unmet clinical needs is given here, as well as a consensus from a panel of experts about technical and clinical requirements for upcoming pilot and pivotal studies in order to accelerate the development and adoption of focused ultrasound for the treatment of primary and secondary liver cancer.
- 1 February 2003
- Published by Elsevier in Clinical Radiology
- Vol. 58 (2) , 112-120
MR-guided Laser Thermal Ablation of Primary and Secondary Liver Tumours
- 1 February 2003
- Published by Elsevier in Clinical Radiology
- Vol. 58 (2) , 112-120
MR-guided Laser Thermal Ablation of Primary and Secondary Liver Tumours
- 22 January 2003
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 17 (2) , 197-205
Feasibility of abdomino-pelvic T1-weighted real-time thermal mapping of laser ablation
- 22 January 2003
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 17 (2) , 197-205
Feasibility of abdomino-pelvic T1-weighted real-time thermal mapping of laser ablation
- 11 December 2002
- Published by Wiley in BJU International
- Vol. 90 (9) , 814-822
Magnetic resonance imaging‐guided laser thermal ablation of renal tumours
Objective To test the hypothesis that magnetic resonance imaging (MRI)‐guided laser thermal ablation (LTA) of inoperable renal tumours is a safe, tolerable and potentially effective treatment . Patients and methods Nine patients (aged 56–81 years) with malignant renal tumours underwent percutaneous LTA under MRI guidance in a 0.5 T open magnet. Real‐time colour thermal mapping was used to monitor tumour ablation, and the follow‐up was with gadolinium‐enhanced MRI at 6 weeks and (where appropriate) 3–4 months after the procedure. Tumour volume and percentage tumour enhancement before and after ablation were compared . The percentage of tumour ablated on real‐time T1‐weighted thermal maps was compared with that on gadolinium‐enhanced follow‐up MRI . Results The mean (range) follow‐up was 16.9 (3–32) months after the first ablation. The mean tumour size did not change significantly, but the mean percentage of viable tumour decreased significantly from 73.7% before to 29.5% after ablation ( P = 0.012, Wilcoxon signed‐ranks test). Thermal maps correlated moderately well with follow‐up MRI in predicting the extent of tumour ablation (Pearson correlation coefficient 0.55). There were two minor and one major complication. Conclusion In this pilot study of patients unsuitable for surgery, MRI‐guided LTA of renal tumours was safe, feasible (being well tolerated by the patient) and significantly reduced enhancing tumour volume by a mean of 45%.
- 11 December 2002
- Published by Wiley in BJU International
- Vol. 90 (9) , 814-822
Magnetic resonance imaging‐guided laser thermal ablation of renal tumours
Objective To test the hypothesis that magnetic resonance imaging (MRI)‐guided laser thermal ablation (LTA) of inoperable renal tumours is a safe, tolerable and potentially effective treatment . Patients and methods Nine patients (aged 56–81 years) with malignant renal tumours underwent percutaneous LTA under MRI guidance in a 0.5 T open magnet. Real‐time colour thermal mapping was used to monitor tumour ablation, and the follow‐up was with gadolinium‐enhanced MRI at 6 weeks and (where appropriate) 3–4 months after the procedure. Tumour volume and percentage tumour enhancement before and after ablation were compared . The percentage of tumour ablated on real‐time T1‐weighted thermal maps was compared with that on gadolinium‐enhanced follow‐up MRI . Results The mean (range) follow‐up was 16.9 (3–32) months after the first ablation. The mean tumour size did not change significantly, but the mean percentage of viable tumour decreased significantly from 73.7% before to 29.5% after ablation ( P = 0.012, Wilcoxon signed‐ranks test). Thermal maps correlated moderately well with follow‐up MRI in predicting the extent of tumour ablation (Pearson correlation coefficient 0.55). There were two minor and one major complication. Conclusion In this pilot study of patients unsuitable for surgery, MRI‐guided LTA of renal tumours was safe, feasible (being well tolerated by the patient) and significantly reduced enhancing tumour volume by a mean of 45%.
- Open Access
- 1 October 2002
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 17 (10) , 2737-2741
Clinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids
BACKGROUND: Fibroids are common benign tumours of the uterus. Percutaneous magnetic resonance (MR) image guided laser ablation provides a minimally invasive, day-case alternative to surgery for the treatment of symptomatic fibroids. METHODS: Women with symptomatic fibroids wishing to avoid surgery were treated with laser ablation. MR thermal mapping ensured that maximal safe energy was applied. Fibroid volume was measured at 3 and 12 months, menstrual blood loss was recorded before and after treatment and a menorrhagia outcomes questionnaire (MOQ) was used to assess satisfaction. RESULTS: A total of 66 patients was treated. There was a significant (P < 0.001) reduction in mean fibroid volume of 31%. This was 41% at 1 year follow-up (P < 0.001). Measured menstrual blood loss in eight patients complaining of excessive bleeding was reduced (P = 0.012). The MOQ total outcome score was not as good as that seen in hysterectomy patients (P = 0.02) but the quality of life/satisfaction score was similar (P = 0.06). CONCLUSION: We have used objective and subjective outcome measures to determine the efficacy of MR guided laser ablation for fibroids. Based on this limited study we are encouraged that this procedure may represent a minimally invasive alternative therapy for fibroids.
- 1 October 2002
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 17 (10) , 2737-2741
Open AccessClinical outcomes following percutaneous magnetic resonance image guided laser ablation of symptomatic uterine fibroids
BACKGROUND: Fibroids are common benign tumours of the uterus. Percutaneous magnetic resonance (MR) image guided laser ablation provides a minimally invasive, day-case alternative to surgery for the treatment of symptomatic fibroids. METHODS: Women with symptomatic fibroids wishing to avoid surgery were treated with laser ablation. MR thermal mapping ensured that maximal safe energy was applied. Fibroid volume was measured at 3 and 12 months, menstrual blood loss was recorded before and after treatment and a menorrhagia outcomes questionnaire (MOQ) was used to assess satisfaction. RESULTS: A total of 66 patients was treated. There was a significant (P < 0.001) reduction in mean fibroid volume of 31%. This was 41% at 1 year follow-up (P < 0.001). Measured menstrual blood loss in eight patients complaining of excessive bleeding was reduced (P = 0.012). The MOQ total outcome score was not as good as that seen in hysterectomy patients (P = 0.02) but the quality of life/satisfaction score was similar (P = 0.06). CONCLUSION: We have used objective and subjective outcome measures to determine the efficacy of MR guided laser ablation for fibroids. Based on this limited study we are encouraged that this procedure may represent a minimally invasive alternative therapy for fibroids.
- Open Access
Ablative therapy for liver tumours
Established ablative therapies for the treatment of primary and secondary liver tumours, including percutaneous ethanol injection, cryotherapy, and radiofrequency ablation, are discussed. Newer techniques such as magnetic resonance imaging guided laser interstitial thermal therapy of liver tumours has produced a median survival rate of 40.8 months after treatment. The merits of this newly emerging technique are discussed, together with future developments, such as focused ultrasound therapy, which holds the promise of non-invasive thermoablation treatment on an outpatient basis.
Open AccessAblative therapy for liver tumours
Established ablative therapies for the treatment of primary and secondary liver tumours, including percutaneous ethanol injection, cryotherapy, and radiofrequency ablation, are discussed. Newer techniques such as magnetic resonance imaging guided laser interstitial thermal therapy of liver tumours has produced a median survival rate of 40.8 months after treatment. The merits of this newly emerging technique are discussed, together with future developments, such as focused ultrasound therapy, which holds the promise of non-invasive thermoablation treatment on an outpatient basis.
- 1 January 2001
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 13 (1) , 37-41
The value of MnDPDP enhancement during MR guided laser interstitial thermoablation of liver tumors
- 1 January 2001
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 13 (1) , 37-41
The value of MnDPDP enhancement during MR guided laser interstitial thermoablation of liver tumors